Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.Don't Miss our Black ...

Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.

近日，西安交通大学第二附属医院心血管病院王洪涛副主任心脏电生理团队，成功完成西北地区首例一站式FARAPULSE脉冲导管消融联合Watchman ...

左心耳封堵（LAAC）技术凭借优异的安全性和有效性，在卒中预防方面为大量房颤患者实现了高效且稳定的生活质量提升和长期预后改善。在过去的十 ...

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Boston Scientific Corp.’s OPTION study demonstrated left atrial appendage closure with the Watchman Flx device reduced risk of stroke compared to management with direct oral anticoagulants or warfarin ...

Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...

Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the ...

The WATCHMAN FLX device showed superior safety with 8.5% major bleeding at 36 months, compared to 18.1% with oral ...

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global clinical trial for its WATCHMAN FLX Left Atrial Appendage Closure (“LAAC ...